EFFECTS OF PERINDOPRIL ON GLUCOSE AND LIPID-METABOLISM IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL-HYPERTENSION AND GLUCOSE-INTOLERANCE

The effect of perindopril, an angiotensin-converting enzyme inhibitor, on glucose and lipid metabolism was evaluated in 12 patients with mil d-to-moderate essential hypertension and glucose intolerance. Perindop ril was administered at a dosage of 2 to 8 mg once daily for 12 weeks. Both the systolic and diastolic blood pressures were significantly re duced throughout the treatment period. There were no significant chang es in the insulinogenic index (DELTAplasma immunoreactive insulin/DELT Aplasma glucose) calculated from the results of 75-g oral glucose tole rance tests performed before and after perindopril treatment. Serum le vels of glycosylated hemoglobin, fructosamine, lipids, lipoproteins, a nd apolipoproteins were also not affected. These results suggest that perindopril can be used effectively to treat hypertension in patients with glucose intolerance without affecting glucose and lipid metabolis m.